BioCentury | May 2, 2016
Company News

Topokine, Allergan deal

...Allergan acquired Topokine for $85 million up front. Topokine shareholders are also eligible for development and...
...XAF5 is in Phase IIb/III testing to treat steatoblepharon. Allergan did not respond to inquiries. Topokine Therapeutics Inc....
BioCentury | Mar 9, 2015
Clinical News

XAF5: Phase II data

...will be presented at the American Academy of Dermatology meeting in San Francisco this month. Topokine Therapeutics Inc....
BioCentury | Nov 25, 2013
Clinical News

XAF5: Phase II started

...placebo-controlled, U.S. Phase II trial to evaluate once-daily topical XAF5 gel in about 72 patients. Topokine Therapeutics Inc....
Items per page:
1 - 3 of 3
BioCentury | May 2, 2016
Company News

Topokine, Allergan deal

...Allergan acquired Topokine for $85 million up front. Topokine shareholders are also eligible for development and...
...XAF5 is in Phase IIb/III testing to treat steatoblepharon. Allergan did not respond to inquiries. Topokine Therapeutics Inc....
BioCentury | Mar 9, 2015
Clinical News

XAF5: Phase II data

...will be presented at the American Academy of Dermatology meeting in San Francisco this month. Topokine Therapeutics Inc....
BioCentury | Nov 25, 2013
Clinical News

XAF5: Phase II started

...placebo-controlled, U.S. Phase II trial to evaluate once-daily topical XAF5 gel in about 72 patients. Topokine Therapeutics Inc....
Items per page:
1 - 3 of 3